

Health Research Group believes the restrictions of Schedule IV are not sufficient to protect the public from the dangers of DPX use and has proposed it be transferred to the most restricted control, Schedule II.

REFERENCES

The following items specifically cited in this notice, as well as a number of other items related to the DPX hearing, are on file and available for inspection in the office of the Hearing Clerk, at the address specified at the beginning of this notice.

1. Petition from Health Research Group, Washington, D.C., to Secretary J. Califano, November 21, 1978.
2. National Academy of Sciences/National Research Council; Report of Panel on Drugs for the Relief of Pain on Darvon Compound, NDA 10-996.
3. Beaver, W. T., "Mild Analgesics, A Review of Their Clinical Pharmacology (Part II)," *American Journal of Medical Science*, 25:576-599, 1966.
4. Miller, R. R., A. Feingold and J. Paxinos, "Propoxyphene Hydrochloride," *Journal of American Medicine*, 213(6):996-1006, 1970.
5. Beaver, W. T., Memorandum to Henry E. Simmons, Director, Bureau of Drugs, Food and Drug Administration, May 18, 1971.
6. Moertel, C. G., D. L. Ahmann, W. F. Taylor, and N. Schwartz, "A Comparative Evaluation of Marketed Analgesic Drugs," *The New England Journal of Medicine*, 286:813-15, 1972.
7. Hopkinson, J. H., IV, et al., "Acetaminophen Versus Propoxyphene Hydrochloride for Relief of Pain in Episiotomy Patients," *The Journal of Clinical Pharmacology*, 113:251-263, 1973.
8. Gruber, C. M., Jr., "Codeine and Propoxyphene in Postepisiotomy Pain," *The Journal of the American Medical Association*, 237:2734-35, 1977.
9. Sunshine, A. J. Slaffa and C. Gruber, Jr., "A Comparative Analgesic Study of Propoxyphene, Fenoprofen, the Combination of Propoxyphene and Fenoprofen, Aspirin, and Placebo," *The Journal of Clinical Pharmacology*, 18:556-563, 1978.
10. Miller, R. R., "Propoxyphene, A Review," *American Journal of Hospital Pharmacy*, 34:413-423, 1977.
11. Propoxyphene Hearings (January 31, February 1 and 5, 1979) of the Monopoly and Anticompetitive Activities Subcommittee of the Select Committee on Small Business, U.S. Senate.
12. Moertel, C. G., D. L. Ahmann, W. F. Taylor, and N. Schwartz, "Relief of Pain by Oral Medications," *The Journal of the American Medical Association*, 229(1):55-59, 1974.
13. Bauer, R. O., A. Baptisti, Jr., and C. M. Gruber, Jr., "Evaluation of Propoxyphene Napsylate Compound in Postpartum Uterine Cramping," *The Journal of Medicine*, 5:317-328, 1974.
14. Miller, R. and D. J. Greenblatt, "Drug Effects in Hospitalized Patients: Experiences of the Boston Collaborative Drug Surveillance Program, 1966-1975," John Wiley & Sons, New York, pp. 162-164, 1975.
15. Jaffe, J. H. and W. R. Martin, "Narcotic Analgesic and Antagonists," in "The Pharmacological Basis of Therapeutics," 5th Ed., Edited by Goodman, L. S., and A. Gilman, MacMillan Publishing Co., Inc., New York, pp. 270-271, 1975.
16. Baselt, R. C. and J. A. Wright, J. E. Turner, and R. H. Cravey, "Propoxyphene and Norpropoxyphene Tissue Concentrations in Fatalities Associated with Propoxyphene Hydrochloride and Propoxyphene Napsylate," *Archives of Toxicology*, 34:145-152, 1975.
17. Finkel, B. S., K. L. McCloskey, G. F. Kiplinger, and I. F. Bennett, "A National Assessment of Propoxyphene in Postmortem Medicolegal Investigation, 1972-1975," *Journal of Forensic Sciences*, 21(4):706-742, 1976.
18. Hine, C. H., J. A. Wright, D. J. Allison, B. G. Stephens, and A. Pasi, Analysis of Fatalities due to Acute Narcotism in a Major Urban Area (unpub.).

PUBLIC HEARINGS

The Food and Drug Administration announces that a public hearing will be held to obtain additional information and recommendations relevant to consideration of further regulatory actions on DPX-containing drug products. The